Cancer Therapeutics
OS Therapies Advances Key Cancer Treatment Toward Regulatory Filings and Plans Animal Health Spin-off
OS Therapies Inc. is progressing its lead cancer drug OST-HER2 toward U.S. and U.K. regulatory submissions while planning to spin off its animal health division into a separate public company, potentially creating significant value for shareholders.
Oncotelic Therapeutics Advances Cancer Pipeline with Phase 3 Candidate and AI Integration
Oncotelic Therapeutics is progressing its RNA-based immunotherapy OT-101 through Phase 3 trials for pancreatic cancer while leveraging strategic partnerships and proprietary AI technology to accelerate drug development across multiple underserved disease areas.
Kairos Pharma to Present at H.C. Wainwright Global Investment Conference
Kairos Pharma's participation in the prestigious H.C. Wainwright conference provides crucial visibility for its innovative cancer therapeutic ENV105, which addresses significant unmet medical needs in drug-resistant cancers.
Calidi Biotherapeutics Appoints Biotech Veteran Eric Poma as CEO to Drive Growth
Calidi Biotherapeutics Inc. has named Eric Poma, PhD, as its new CEO and board member, marking a strategic step to advance its innovative cancer therapies towards commercialization.
Bio-Path Holdings Advances in RNAi Therapeutics with Promising Clinical Trials
Bio-Path Holdings, Inc. makes strides in RNA interference therapeutics, with its DNAbilize® platform showing potential in treating cancers, obesity, and type 2 diabetes, marking a significant step forward in biotechnology.